10 results
Keyword Lifitegrast Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lifitegrast
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Ophthalmology
PIP number: EMEA-001979-PIP01-16, Route(s) of administration: Ophthalmic use, Pharmaceutical form(s): Eye drops, solution, Solution
Decision date: 05/10/2016, Last updated: 18/12/2017, Compliance check: XKey facts Lifitegrast OphthalmologyP/0263/2016EMEA-001979-PIP01-16 … product specific waiver for lifitegrast (EMEA-001979-PIP01-16) PDF … product specific waiver for lifitegrast (EMEA-001979-PIP01-16) in … -
List item
Withdrawn application: Xiidra
date of withdrawal: 18/06/2020, Initial authorisation, Last updated: 19/08/2020Xiidra Xiidra Lifitegrast … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020
CHMP, Last updated: 26/06/2020lifitegrast) and … -
List item
Paediatric Committee (PDCO): 17-19 August 2016
European Medicines Agency, London, UK, from 17/08/2016 to 19/08/2016, Last updated: 17/08/2016EMA/PDCO/567509/2016 Page 2/5 • lifitegrast, EMEA-001979-PIP01-16, from … -
List item
Paediatric Committee (PDCO): 20-22 July 2016
European Medicines Agency, London, UK, from 20/07/2016 to 22/07/2016, Last updated: 04/08/2016 -
List item
PDCO: meeting archive 2015-2017
Last updated: 19/04/2022 -
List item
News: Progress on science, medicines and health
Last updated: 10/05/2017 -
List item
Annual reports and work programmes
Last updated: 10/06/2022 -
List item
News: Annual report 2020 published
Last updated: 14/06/2021 -
List item
Guidance documents
Last updated: 19/07/2022